© 2008 European Society of Cardiology
The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure
a Department of Family Medicine, University of Michigan Ann Arbor, MI, United States
b Department of Biostatistics, University of Michigan Ann Arbor, MI, United States
c Department of Internal Medicine (Division of Cardiovascular Medicine), University of Michigan Ann Arbor, MI, United States
d Center for Statistical Consulting and Research, University of Michigan Ann Arbor, MI, United States
e Michigan Integrative Medicine Research Center, University of Michigan Ann Arbor, MI, United States
* Corresponding author. Department of Family Medicine, University of Michigan Medical Center, 715 E. Huron St., Suite 2E, Ann Arbor, MI, 48104, United States. Tel.: +1 734 998 7715; fax: +1 734 998 7720. E-mail address: szick{at}umich.edu
 |
Abstract |
|---|
Aim: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients.
Methods: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling.
Results: Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1–13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF
35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group.
Conclusions: CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression.
Key Words: Hawthorn • Heart failure progression • Crataegus Special Extract WS 1442 • Crataegus oxycantha
Received November 19, 2007; Revised March 21, 2008; Accepted April 16, 2008
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Zick, B. M. Vautaw, B. Gillespie, and K. D. Aaronson Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial Eur J Heart Fail, October 1, 2009; 11(10): 990 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Furey and M. Tassell Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (Crataegus spp.) Eur J Heart Fail, December 1, 2008; 10(12): 1153 - 1157. [Full Text] [PDF]
|
|